PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.67%
G&A change of 73.67% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.67%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
73.67%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
5.36%
Interest expense change of 5.36% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 5.05%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 4.58%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
5.36%
Other expenses growth below 50% of Drug Manufacturers - Specialty & Generic median of 13.28%. Joel Greenblatt would investigate efficiency.
-89.61%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 5.43%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.61%
Net income decline while Drug Manufacturers - Specialty & Generic median is 4.27%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-90.91%
EPS decline while Drug Manufacturers - Specialty & Generic median is 5.16%. Seth Klarman would investigate causes.
-90.91%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 3.75%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.